Skip to content
Inciteful Med

Understanding Prognosis and Risk Scores

Last updated:

Primary Sclerosing Cholangitis (PSC) prognosis is estimated using models like the Revised Mayo Risk Score, UK-PSC, PREsTo, and FibroScan tests. While these tools help predict long-term liver health, they are statistical averages, not absolute guarantees of your individual disease course.

Key Takeaways

  • • Prognostic models like the Revised Mayo Risk Score and UK-PSC use your blood test results to estimate long-term liver health and transplant-free survival.
  • • The PREsTo score uses nine lab values to accurately predict hepatic decompensation, such as fluid buildup in the abdomen.
  • • FibroScan uses sound waves to measure liver stiffness, with scores above 10.5 kPa indicating significant scarring and higher complication risks.
  • • Risk scores help guide monitoring frequency and transplant evaluation, but they are population-based estimates rather than individual guarantees.

Living with Primary Sclerosing Cholangitis (PSC) often means dealing with uncertainty. To help manage this, doctors use prognostic models—mathematical tools that combine your blood test results and medical history to estimate how the disease might progress [1]. While these scores are helpful for planning and clinical trials, it is important to remember they are based on data from thousands of people; they are statistical “best guesses” and cannot perfectly predict what will happen to you as an individual [2][3].

The Revised Mayo Risk Score (rMRS)

For over 20 years, the Revised Mayo Risk Score has been the standard tool for predicting “transplant-free survival” [1]. Your doctor calculates this score using five key pieces of information:

  1. Age: Your current age.
  2. Bilirubin: A measure of how well your liver is clearing bile [4].
  3. Albumin: A protein made by the liver; low levels can indicate reduced liver function [5].
  4. AST (Aspartate Aminotransferase): An enzyme that rises when liver cells are damaged [4].
  5. Variceal Bleeding: Whether you have ever had bleeding from swollen veins in your esophagus [4].

Newer, More Accurate Models

In recent years, researchers have developed “second-generation” models that are often more accurate than the original Mayo score because they include more variables, such as platelet counts and Alkaline Phosphatase (ALP) levels [6][5].

  • UK-PSC Score: This tool can be used at the time of your diagnosis and during your routine follow-ups. It is particularly good at predicting long-term (10-year) outcomes [7]. In studies, it significantly outperformed the Mayo score in accuracy [7][1].
  • PREsTo (Primary Sclerosing Risk Estimate Tool): This model uses nine different lab values to predict hepatic decompensation—the point when the liver struggles to function and complications like fluid in the abdomen (ascites) occur [5]. PREsTo is currently considered one of the most accurate tools available for this specific purpose [1][5].

Measuring Stiffness: FibroScan

In the past, the only way to measure liver scarring (fibrosis) was a painful biopsy. Today, doctors use FibroScan (also called transient elastography) [8].

  • How it works: It uses sound waves to measure the “stiffness” of your liver. The more scarred the liver is, the stiffer it becomes [8][9].
  • The Baseline: A normal, healthy liver typically has a stiffness score of around 4 to 6 kPa (kilopascals).
  • The Results: A score above 10.5 to 11.1 kPa suggests significant scarring and a higher risk of future complications [10][11]. Doctors often combine your FibroScan result with your MRI (MRCP) findings to get a complete picture of your liver health [10].

Interpretation Guide

When your doctor discusses these scores with you, use this general guide to understand the categories:

Risk Level Score Interpretation Typical Management
Low Risk Mayo Score <0<0; FibroScan <10<10 kPa Routine monitoring every 6–12 months [12][10].
Intermediate Mayo Score 0–2; FibroScan 10–11 kPa More frequent monitoring; potential clinical trial eligibility [12][10].
High Risk Mayo Score >2>2; FibroScan >11>11 kPa Discussion of transplant evaluation and closer cancer surveillance [12][11].

A Note on Anxiety: It is natural to feel anxious when seeing a “risk score.” However, many patients with high scores remain stable for years, while others with low scores may experience sudden changes [13]. These tools are meant to help your doctor stay proactive—not to determine your destiny.

Frequently Asked Questions

What is the Revised Mayo Risk Score for PSC?
The Revised Mayo Risk Score is a mathematical tool that estimates transplant-free survival for PSC patients. Your doctor calculates it using five key pieces of information: your age, bilirubin, albumin, AST levels, and history of variceal bleeding.
How is the UK-PSC score different from the Mayo score?
The UK-PSC score is a newer prognostic tool that is particularly accurate at predicting 10-year outcomes for PSC patients. It includes additional variables like platelet counts and alkaline phosphatase (ALP) levels, making it more accurate than the original Mayo score.
What does the PREsTo score measure?
The PREsTo score uses nine different lab values to predict hepatic decompensation. Decompensation is the point when the liver struggles to function normally, leading to severe complications like ascites (fluid in the abdomen).
What is a normal FibroScan result for someone with PSC?
A normal, healthy liver typically has a FibroScan stiffness score between 4 and 6 kPa. In patients with PSC, a score above 10.5 to 11.1 kPa suggests significant liver scarring and a higher risk of future complications.
Do my risk scores guarantee how my disease will progress?
No, risk scores are statistical estimates based on large groups of people and cannot perfectly predict individual outcomes. Many patients with high scores remain stable for years, while these tools primarily help your doctor stay proactive with your monitoring and care.

Questions for Your Doctor

  • • What is my current Revised Mayo Risk Score (rMRS), and which of my lab results are affecting it the most?
  • • Could we calculate my 'UK-PSC' score to get a better sense of my 10-year outlook?
  • • My FibroScan result was [X] kPa—how does this liver stiffness measurement change my overall risk category compared to a healthy baseline?
  • • How often should we repeat these risk scores and elastography tests to track my disease progression?
  • • Are these scores being used to determine when I should be referred for a liver transplant evaluation?

Questions for You

  • • Do I have a copy of my most recent blood work (bilirubin, albumin, AST, and platelets) to help my doctor calculate these scores?
  • • Have I ever experienced symptoms of 'decompensation,' such as swelling in my abdomen (ascites) or vomiting blood (variceal bleeding)?
  • • When I look at my risk scores, am I remembering that these are based on 'large populations' and don't tell the whole story of my individual health?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Noninvasive prognostic models, imaging, and elastography to predict clinical events in primary sclerosing cholangitis: A review.

    Russo MW

    World journal of hepatology 2023; (15(9)):1013-1020 doi:10.4254/wjh.v15.i9.1013.

    PMID: 37900215
  2. 2

    Primary sclerosing cholangitis: what is new in the therapeutic landscape.

    Curto A, Cristoferi L, Carbone M, et al.

    Current opinion in immunology 2025; (96()):102613 doi:10.1016/j.coi.2025.102613.

    PMID: 40683116
  3. 3

    Primary sclerosing cholangitis: A review and update.

    Tabibian JH, Bowlus CL

    Liver research (Beijing, China) 2017; (1(4)):221-230 doi:10.1016/j.livres.2017.12.002.

    PMID: 29977644
  4. 4

    Performance of the Mayo Risk Score in Predicting Transplant and Mortality in a Single-Center U.S. Cohort of Primary Sclerosing Cholangitis.

    Kahan T, Marenco-Flores A, Amaris NR, et al.

    Journal of clinical medicine 2025; (14(6)) doi:10.3390/jcm14062098.

    PMID: 40142906
  5. 5

    Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes of the Disease: A Derivation and Validation Study Using Machine Learning.

    Eaton JE, Vesterhus M, McCauley BM, et al.

    Hepatology (Baltimore, Md.) 2020; (71(1)):214-224 doi:10.1002/hep.30085.

    PMID: 29742811
  6. 6

    Systematic Review of Prognostic Models Compared to the Mayo Risk Score for Primary Sclerosing Cholangitis.

    Schmeltzer PA, Russo MW

    Journal of clinical medicine 2021; (10(19)) doi:10.3390/jcm10194476.

    PMID: 34640494
  7. 7

    Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System.

    Goode EC, Clark AB, Mells GF, et al.

    Hepatology (Baltimore, Md.) 2019; (69(5)):2120-2135 doi:10.1002/hep.30479.

    PMID: 30566748
  8. 8

    Validation of Transient Elastography and Comparison with Spleen Length Measurement for Staging of Fibrosis and Clinical Prognosis in Primary Sclerosing Cholangitis.

    Ehlken H, Wroblewski R, Corpechot C, et al.

    PloS one 2016; (11(10)):e0164224 doi:10.1371/journal.pone.0164224.

    PMID: 27723798
  9. 9

    Liver Elastography in Primary Sclerosing Cholangitis Patients Using Three Different Scanner Systems.

    Mjelle AB, Fossdal G, Gilja OH, Vesterhus M

    Ultrasound in medicine & biology 2020; (46(8)):1854-1864 doi:10.1016/j.ultrasmedbio.2020.03.025.

    PMID: 32507342
  10. 10

    The Complementary Value of Magnetic Resonance Imaging and Vibration-Controlled Transient Elastography for Risk Stratification in Primary Sclerosing Cholangitis.

    Cazzagon N, Lemoinne S, El Mouhadi S, et al.

    The American journal of gastroenterology 2019; (114(12)):1878-1885 doi:10.14309/ajg.0000000000000461.

    PMID: 31738286
  11. 11

    Systematic review: non-invasive prognostic tests for primary sclerosing cholangitis.

    Mazhar A, Russo MW

    Alimentary pharmacology & therapeutics 2021; (53(7)):774-783 doi:10.1111/apt.16296.

    PMID: 33608929
  12. 12

    Correlation between quantitative liver and spleen volumes and disease severity in primary sclerosing cholangitis as determined by Mayo risk score.

    Khoshpouri P, Ameli S, Ghasabeh MA, et al.

    European journal of radiology 2018; (108()):254-260 doi:10.1016/j.ejrad.2018.10.006.

    PMID: 30396665
  13. 13

    Longitudinal Comparison of Currently Used Risk Scores for Prognostication of Primary Sclerosing Cholangitis (PSC) in a Hungarian Bicenter PSC Cohort.

    Ven PL, Tornai D, Toth B, et al.

    Diagnostics (Basel, Switzerland) 2025; (15(17)) doi:10.3390/diagnostics15172166.

    PMID: 40941654

This page explains Primary Sclerosing Cholangitis (PSC) risk scores and prognostic tools for educational purposes. Your hepatologist or gastroenterologist is the best source for interpreting your specific test results and outlook.

Stay up to date

Get notified when new research about Primary sclerosing cholangitis is published.

No spam. Unsubscribe anytime.